Ser71
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.7
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser71  -  TH (human)

Site Information
RFIGRRQsLIEDARK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448545

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 1 ) , mass spectrometry ( 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 )
Disease tissue studied:
adrenal cancer ( 1 ) , pheochromocytoma ( 1 ) , gastric cancer ( 5 ) , gastric carcinoma ( 5 ) , liver cancer ( 10 ) , hepatocellular carcinoma, surrounding tissue ( 9 ) , neuroblastoma ( 2 , 4 , 8 )
Relevant cell line - cell type - tissue:
'brain, substantia nigra' ( 1 ) , hepatocyte-liver ( 9 ) , Jurkat (T lymphocyte) ( 6 , 7 ) , K562 (erythroid) ( 11 ) , LAN-6 (neural crest) ( 2 , 8 ) , liver ( 10 ) , MKN-45 (gastric) ( 5 ) , NB10 (neural crest) ( 4 ) , NPC (neural crest) ( 4 ) , PC-12 (chromaffin) ( 1 ) , SH-SY5Y (neural crest) ( 2 ) , SK-N-BE(2) (neural crest) ( 2 ) , SMS-KCN-A (neural crest) ( 2 )

Upstream Regulation
Putative in vivo kinases:
PAK4 (human) ( 1 )
Kinases, in vitro:
CAMK2A (human) ( 15 ) , CAMK2A (rat) ( 14 ) , MAPKAPK2 (human) ( 13 , 14 ) , PAK4 (human) ( 1 ) , PKACA (cow) ( 14 ) , PKACA (human) ( 12 , 13 , 15 ) , RSK2 (human) ( 14 )
Phosphatases, in vitro:
PPP2CA (human) ( 13 )

Downstream Regulation
Effects of modification on TH:
enzymatic activity, induced ( 14 )

Disease / Diagnostics Relevance
Relevant diseases:
Parkinson's disease ( 1 )

References 

1

Won SY, et al. (2021) cAMP Response Element Binding-Protein- and Phosphorylation-Dependent Regulation of Tyrosine Hydroxylase by PAK4: Implications for Dopamine Replacement Therapy. Mol Cells 44, 493-499
34238765   Curated Info

2

Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130
25884760   Curated Info

3

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

4

DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513
24349301   Curated Info

5

Guo A (2011) CST Curation Set: 11300; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

6

Possemato A (2010) CST Curation Set: 10145; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

7

Possemato A (2010) CST Curation Set: 10144; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

8

Guo A (2010) CST Curation Set: 9943; Year: 2010; Biosample/Treatment: cell line, LAN-6/untreated; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

9

Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9
20166139   Curated Info

10

Gu T (2009) CST Curation Set: 6575; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

11

Stokes M (2008) CST Curation Set: 4605; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

12

Lehmann IT, et al. (2006) Differential regulation of the human tyrosine hydroxylase isoforms via hierarchical phosphorylation. J Biol Chem 281, 17644-51
16644734   Curated Info

13

Kleppe R, Toska K, Haavik J (2001) Interaction of phosphorylated tyrosine hydroxylase with 14-3-3 proteins: evidence for a phosphoserine 40-dependent association. J Neurochem 77, 1097-107
11359875   Curated Info

14

Sutherland C, et al. (1993) Phosphorylation and activation of human tyrosine hydroxylase in vitro by mitogen-activated protein (MAP) kinase and MAP-kinase-activated kinases 1 and 2. Eur J Biochem 217, 715-22
7901013   Curated Info

15

Le Bourdellès B, et al. (1991) Phosphorylation of human recombinant tyrosine hydroxylase isoforms 1 and 2: an additional phosphorylated residue in isoform 2, generated through alternative splicing. J Biol Chem 266, 17124-30
1680128   Curated Info